Why Did Hemispherx Crash Yesterday?
Hemispherx Biopharma (HEB – $0.32) lost more than 38% of its market value yesterady because it announced that its PDUFA date would be extended by three months. A small recap. In July of 2008 the U.S. Food and Drug Administration (FDA) accepted for review the Company’s New Drug Application (NDA) for Ampligen to treat Chronic Fatigue Syndrome (CFS). Hemispherx is […]
Read more